The free-radical–trapping agent NXY-059 showed promise as a neuroprotectant in the Stroke–Acute Ischemic NXY Treatment I (SAINT I) trial, reducing disability when given to patients who had acute ...
August 10, 2007 — Disappointing results of the Stroke Acute Ischemic NXY-059 Trial (SAINT II), a randomized study of the investigational neuroprotectant NXY-059 ( Cerovive, AstraZeneca), show no ...
Acute ischemic stroke is a major cause of death in industrialized countries and is usually treated with thrombolysis using alteplase. This treatment, however, must be started within 3 h of stroke ...
The free-radical-trapping agent NXY-059 can reduce the amount of permanent brain damage after stroke in animal models. Whether NXY-059 therapy can improve outcomes in humans is not known. The ...
To the Editor: In the article by Lees et al. (Feb. 9 issue) 1 about the Stroke–Acute Ischemic NXY Treatment (SAINT I) trial, the abstract suggests significant reduction of hemorrhagic transformation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results